Polyamines: the pivotal amines in influencing the tumor microenvironment.
Amino acid metabolism
Immunotherapy
Polyamine
Tumor microenvironment
Journal
Discover oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
18 May 2024
18 May 2024
Historique:
received:
31
12
2023
accepted:
11
05
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
18
5
2024
Statut:
epublish
Résumé
Cellular proliferation, function and survival is reliant upon maintaining appropriate intracellular polyamine levels. Due to increased metabolic needs, cancer cells elevate their polyamine pools through coordinated metabolism and uptake. High levels of polyamines have been linked to more immunosuppressive tumor microenvironments (TME) as polyamines support the growth and function of many immunosuppressive cell types such as MDSCs, macrophages and regulatory T-cells. As cancer cells and other pro-tumorigenic cell types are highly dependent on polyamines for survival, pharmacological modulation of polyamine metabolism is a promising cancer therapeutic strategy. This review covers the roles of polyamines in various cell types of the TME including both immune and stromal cells, as well as how competition for nutrients, namely polyamine precursors, influences the cellular landscape of the TME. It also details the use of polyamines as biomarkers and the ways in which polyamine depletion can increase the immunogenicity of the TME and reprogram tumors to become more responsive to immunotherapy.
Identifiants
pubmed: 38761252
doi: 10.1007/s12672-024-01034-9
pii: 10.1007/s12672-024-01034-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
173Informations de copyright
© 2024. The Author(s).
Références
Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61(9):880–94.
pubmed: 19603518
pmcid: 2753421
doi: 10.1002/iub.230
Smirnov IV, Dimitrov SI, Makarov VL. Polyamine-DNA interactions. Condensation of chromatin and naked DNA. J Biomol Struct Dyn. 1988;5(5):1149–61.
pubmed: 3271502
doi: 10.1080/07391102.1988.10506455
Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4(10):781–92.
pubmed: 15510159
doi: 10.1038/nrc1454
Casero RA, MurrayStewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18(11):681–95.
pubmed: 30181570
pmcid: 6487480
doi: 10.1038/s41568-018-0050-3
Casero RA, Pegg AE. Polyamine catabolism and disease. Biochem J. 2009;421(3):323–38.
pubmed: 19589128
doi: 10.1042/BJ20090598
Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA. 1993;90(16):7804–8.
pubmed: 8356088
pmcid: 47231
doi: 10.1073/pnas.90.16.7804
Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol. 1994;14(9):5741–7.
pubmed: 8065308
pmcid: 359099
Packham G, Cleveland JL. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol Immunol. 1995;194:283–90.
pubmed: 7895500
Roy UK, et al. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol Carcinog. 2008;47(7):538–53.
pubmed: 18176934
doi: 10.1002/mc.20414
Lan L, Trempus C, Gilmour SK. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res. 2000;60(20):5696–703.
pubmed: 11059762
Ignatenko NA, et al. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog. 2004;39(2):91–102.
pubmed: 14750214
doi: 10.1002/mc.10166
Funakoshi-Tago M, et al. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. PLoS ONE. 2013;8(1): e52844.
pubmed: 23300995
pmcid: 3536786
doi: 10.1371/journal.pone.0052844
Hogarty MD, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008;68(23):9735–45.
pubmed: 19047152
pmcid: 2596661
doi: 10.1158/0008-5472.CAN-07-6866
Kucharzewska P, et al. The polyamines regulate endothelial cell survival during hypoxic stress through PI3K/AKT and MCL-1. Biochem Biophys Res Commun. 2009;380(2):413–8.
pubmed: 19250631
doi: 10.1016/j.bbrc.2009.01.097
Wang C, et al. Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells. Oncotarget. 2017;8(1):1092–109.
pubmed: 27901475
doi: 10.18632/oncotarget.13582
Chaturvedi R, et al. Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA. Gastroenterology. 2011;141(5):1696-708.e12.
pubmed: 21839041
doi: 10.1053/j.gastro.2011.07.045
Xu H, et al. Spermine oxidation induced by Helicobacter pylori results in apoptosis and DNA damage: implications for gastric carcinogenesis. Cancer Res. 2004;64(23):8521–5.
pubmed: 15574757
doi: 10.1158/0008-5472.CAN-04-3511
Travers M, et al. DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer. Cancer Res. 2019;79(13):3445–54.
pubmed: 31088836
pmcid: 6606334
doi: 10.1158/0008-5472.CAN-18-4018
Nakkina SP, et al. DFMO improves survival and increases immune cell infiltration in association with MYC downregulation in the pancreatic tumor microenvironment. Int J Mol Sci. 2021;22(24):13175.
pubmed: 34947972
pmcid: 8706739
doi: 10.3390/ijms222413175
Shi HX, et al. Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma. Cell Commun Signal. 2022;20(1):175.
pubmed: 36348350
pmcid: 9644467
doi: 10.1186/s12964-022-00981-6
Dryja P, et al. Inhibition of polyamine biosynthesis using difluoromethylornithine acts as a potent immune modulator and displays therapeutic synergy with PD-1-blockade. J Immunother. 2021;44(8):283–91.
pubmed: 34133404
pmcid: 8416699
doi: 10.1097/CJI.0000000000000379
Zhang E, et al. Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer. Cancer Cell Int. 2023;23(1):96.
pubmed: 37202800
pmcid: 10197465
doi: 10.1186/s12935-023-02892-z
Kang J, et al. Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing. Nat Metab. 2024;6(1):153–68.
pubmed: 38243132
doi: 10.1038/s42255-023-00955-z
Tsuji T, et al. Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme. Oncogene. 2001;20(1):24–33.
pubmed: 11244502
doi: 10.1038/sj.onc.1204051
Yamamoto D, et al. Ornithine decarboxylase antizyme induces hypomethylation of genome DNA and histone H3 lysine 9 dimethylation (H3K9me2) in human oral cancer cell line. PLoS ONE. 2010;5(9): e12554.
pubmed: 20838441
pmcid: 2933235
doi: 10.1371/journal.pone.0012554
Frostesjö L, et al. Interference with DNA methyltransferase activity and genome methylation during F9 teratocarcinoma stem cell differentiation induced by polyamine depletion. J Biol Chem. 1997;272(7):4359–66.
pubmed: 9020157
doi: 10.1074/jbc.272.7.4359
Casero RA, Pegg AE. Spermidine/spermine N1-acetyltransferase—the turning point in polyamine metabolism. FASEB J. 1993;7(8):653–61.
pubmed: 8500690
doi: 10.1096/fasebj.7.8.8500690
Pegg AE. Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am J Physiol Endocrinol Metab. 2008;294(6):E995-1010.
pubmed: 18349109
doi: 10.1152/ajpendo.90217.2008
Morgan DM. Polyamine oxidases—enzymes of unknown function? Biochem Soc Trans. 1998;26(4):586–91.
pubmed: 10047787
doi: 10.1042/bst0260586
Wang Y, et al. Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): potential role in determining drug sensitivity. Cancer Chemother Pharmacol. 2005;56(1):83–90.
pubmed: 15791459
doi: 10.1007/s00280-004-0936-5
Poulin R, Casero RA, Soulet D. Recent advances in the molecular biology of metazoan polyamine transport. Amino Acids. 2012;42(2–3):711–23.
pubmed: 21814785
doi: 10.1007/s00726-011-0987-y
Xuan M, et al. Polyamines: their significance for maintaining health and contributing to diseases. Cell Commun Signal. 2023;21(1):348.
pubmed: 38049863
pmcid: 10694995
doi: 10.1186/s12964-023-01373-0
Hölttä E. Oxidation of spermidine and spermine in rat liver: purification and properties of polyamine oxidase. Biochemistry. 1977;16(1):91–100.
pubmed: 12798
doi: 10.1021/bi00620a015
Wang Y, Casero RA. Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both? J Biochem. 2006;139(1):17–25.
pubmed: 16428315
doi: 10.1093/jb/mvj021
Wang Y, et al. Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res. 2001;61(14):5370–3.
pubmed: 11454677
Moghe A, et al. Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci. 2015;143(2):242–55.
pubmed: 25628402
pmcid: 4306719
doi: 10.1093/toxsci/kfu233
Sharmin S, et al. Polyamine cytotoxicity in the presence of bovine serum amine oxidase. Biochem Biophys Res Commun. 2001;282(1):228–35.
pubmed: 11263996
doi: 10.1006/bbrc.2001.4569
Houen G, Bock K, Jensen AL. HPLC and NMR investigation of the serum amine oxidase catalyzed oxidation of polyamines. Acta Chem Scand. 1994;48(1):52–60.
pubmed: 8130014
doi: 10.3891/acta.chem.scand.48-0052
Holbert CE, et al. Autophagy induction by exogenous polyamines is an artifact of bovine serum amine oxidase activity in culture serum. J Biol Chem. 2020;295(27):9061–8.
pubmed: 32430398
pmcid: 7335804
doi: 10.1074/jbc.RA120.013867
Murray-Stewart T, et al. Nuclear localization of human spermine oxidase isoforms—possible implications in drug response and disease etiology. FEBS J. 2008;275(11):2795–806.
pubmed: 18422650
pmcid: 3631774
doi: 10.1111/j.1742-4658.2008.06419.x
Ha HC, et al. The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci USA. 1998;95(19):11140–5.
pubmed: 9736703
pmcid: 21609
doi: 10.1073/pnas.95.19.11140
Ha HC, et al. Structural specificity of polyamines and polyamine analogues in the protection of DNA from strand breaks induced by reactive oxygen species. Biochem Biophys Res Commun. 1998;244(1):298–303.
pubmed: 9514920
doi: 10.1006/bbrc.1998.8258
Murray-Stewart T, et al. Epigenetic silencing of miR-124 prevents spermine oxidase regulation: implications for Helicobacter pylori-induced gastric cancer. Oncogene. 2016;35(42):5480–8.
pubmed: 27041578
pmcid: 5050049
doi: 10.1038/onc.2016.91
Murray-Stewart T, et al. Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047. PLoS ONE. 2017;12(4): e0175917.
pubmed: 28423064
pmcid: 5396973
doi: 10.1371/journal.pone.0175917
Pledgie-Tracy A, et al. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother Pharmacol. 2010;65(6):1067–81.
pubmed: 19727732
doi: 10.1007/s00280-009-1112-8
Zhu Y, et al. Self-immolative polycations as gene delivery vectors and prodrugs targeting polyamine metabolism in cancer. Mol Pharm. 2015;12(2):332–41.
pubmed: 25153488
doi: 10.1021/mp500469n
Pledgie A, et al. Spermine oxidase SMO(PAOh1), not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H
pubmed: 16207710
doi: 10.1074/jbc.M508177200
Zhu Y, et al. The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics. Genomics. 2022;114(1):125–37.
pubmed: 34843906
doi: 10.1016/j.ygeno.2021.11.028
Chen Y, et al. c-MYC-driven polyamine metabolism in ovarian cancer: from pathogenesis to early detection and therapy. Cancers. 2023;15(3):623.
pubmed: 36765581
pmcid: 9913358
doi: 10.3390/cancers15030623
Bachmann AS, Geerts D. Polyamine synthesis as a target of MYC oncogenes. J Biol Chem. 2018;293(48):18757–69.
pubmed: 30404920
pmcid: 6290138
doi: 10.1074/jbc.TM118.003336
Chalishazar MD, et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin Cancer Res. 2019;25(16):5107–21.
pubmed: 31164374
pmcid: 6697617
doi: 10.1158/1078-0432.CCR-18-4140
Cederbaum SD, et al. Arginases I and II: do their functions overlap? Mol Genet Metab. 2004;81(Suppl 1):S38-44.
pubmed: 15050972
doi: 10.1016/j.ymgme.2003.10.012
Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 2001;61(3):1100–6.
pubmed: 11221839
Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336(Pt 1):1–17.
pubmed: 9806879
pmcid: 1219836
doi: 10.1042/bj3360001
Lee MS, et al. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature. 2023;616(7956):339–47.
pubmed: 36991126
pmcid: 10929664
doi: 10.1038/s41586-023-05891-2
Ginguay A, et al. Ornithine aminotransferase, an important glutamate-metabolizing enzyme at the crossroads of multiple metabolic pathways. Biology. 2017;6(1):18.
pubmed: 28272331
pmcid: 5372011
doi: 10.3390/biology6010018
De Ingeniis J, et al. Functional specialization in proline biosynthesis of melanoma. PLoS ONE. 2012;7(9): e45190.
pubmed: 23024808
pmcid: 3443215
doi: 10.1371/journal.pone.0045190
Albaugh VL, Mukherjee K, Barbul A. Proline precursors and collagen synthesis: biochemical challenges of nutrient supplementation and wound healing. J Nutr. 2017;147(11):2011–7.
pubmed: 28978679
pmcid: 5657141
doi: 10.3945/jn.117.256404
Albina JE, Abate JA, Mastrofrancesco B. Role of ornithine as a proline precursor in healing wounds. J Surg Res. 1993;55(1):97–102.
pubmed: 8105150
doi: 10.1006/jsre.1993.1114
Hu CA, et al. Human Delta1-pyrroline-5-carboxylate synthase: function and regulation. Amino Acids. 2008;35(4):665–72.
pubmed: 18401542
pmcid: 2707934
doi: 10.1007/s00726-008-0075-0
Craze ML, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer. 2018;118(2):258–65.
pubmed: 29169183
doi: 10.1038/bjc.2017.387
Liu W, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA. 2012;109(23):8983–8.
pubmed: 22615405
pmcid: 3384197
doi: 10.1073/pnas.1203244109
Marco-Marín C, et al. Δ1-pyrroline-5-carboxylate synthetase deficiency: an emergent multifaceted urea cycle-related disorder. J Inherit Metab Dis. 2020;43(4):657–70.
pubmed: 32017139
doi: 10.1002/jimd.12220
Colonna MB, et al. Functional assessment of homozygous ALDH18A1 variants reveals alterations in amino acid and antioxidant metabolism. Hum Mol Genet. 2023;32(5):732–44.
pubmed: 36067040
doi: 10.1093/hmg/ddac226
Harada D, et al. Oral administration of L-ornithine increases the content of both collagen constituting amino acids and polyamines in mouse skin. Biochem Biophys Res Commun. 2019;512(4):712–5.
pubmed: 30926170
doi: 10.1016/j.bbrc.2019.03.147
McKay TB, et al. Arginine supplementation promotes extracellular matrix and metabolic changes in keratoconus. Cells. 2021;10(8):2076.
pubmed: 34440845
pmcid: 8394349
doi: 10.3390/cells10082076
Chen CL, et al. Arginine signaling and cancer metabolism. Cancers. 2021;13(14):3541.
pubmed: 34298755
pmcid: 8306961
doi: 10.3390/cancers13143541
Duan Q, et al. Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial–mesenchymal transition. Oncol Rep. 2016;36(1):551–8.
pubmed: 27176594
doi: 10.3892/or.2016.4780
Lian J, et al. The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. Front Immunol. 2022;13: 912279.
pubmed: 36119047
pmcid: 9479087
doi: 10.3389/fimmu.2022.912279
Chin A, et al. Polyamine depletion strategies in cancer: remodeling the tumor immune microenvironment to enhance anti-tumor responses. Med Sci. 2022;10(2):31.
Hesterberg RS, Cleveland JL, Epling-Burnette PK. Role of polyamines in immune cell functions. Med Sci. 2018;6(1):22.
Chia TY, Zolp A, Miska J. Polyamine immunometabolism: central regulators of inflammation, cancer and autoimmunity. Cells. 2022;11(5):896.
pubmed: 35269518
pmcid: 8909056
doi: 10.3390/cells11050896
Holbert CE, et al. Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nat Rev Cancer. 2022;22(8):467–80.
pubmed: 35477776
pmcid: 9339478
doi: 10.1038/s41568-022-00473-2
Hiratsuka H, et al. Immunohistologic detection of lymphocyte subpopulations infiltrating in human oral cancer with special reference to its clinical significance. Cancer. 1984;53(11):2456–66.
pubmed: 6201260
doi: 10.1002/1097-0142(19840601)53:11<2456::AID-CNCR2820531116>3.0.CO;2-6
Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46–62.
pubmed: 32243795
pmcid: 8900215
doi: 10.1016/j.cell.2020.03.001
Bowlin TL, McKown BJ, Sunkara PS. Increased ornithine decarboxylase activity and polyamine biosynthesis are required for optimal cytolytic T lymphocyte induction. Cell Immunol. 1987;105(1):110–7.
pubmed: 3102080
doi: 10.1016/0008-8749(87)90060-8
Bowlin TL, McKown BJ, Schroeder KK. Methyl-acetylenicputrescine (MAP), an inhibitor of polyamine biosynthesis, reduces the frequency and cytolytic activity of alloantigen-induced LyT 2.2 positive lymphocytes in vivo. Int J Immunopharmacol. 1989;11(3):259–625.
pubmed: 2786857
doi: 10.1016/0192-0561(89)90163-X
Puleston DJ, et al. Polyamine metabolism is a central determinant of helper T cell lineage fidelity. Cell. 2021;184(16):4186-4202.e20.
pubmed: 34216540
pmcid: 8358979
doi: 10.1016/j.cell.2021.06.007
Wu R, et al. De novo synthesis and salvage pathway coordinately regulate polyamine homeostasis and determine T cell proliferation and function. Sci Adv. 2020;6(51): eabc4275.
pubmed: 33328226
pmcid: 7744078
doi: 10.1126/sciadv.abc4275
Carr EL, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010;185(2):1037–44.
pubmed: 20554958
doi: 10.4049/jimmunol.0903586
Choi BS, et al. Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages. J Leukoc Biol. 2009;85(2):268–77.
pubmed: 19008294
doi: 10.1189/jlb.0508310
Gnanaprakasam JN, Wang R. MYC in regulating immunity: metabolism and beyond. Genes. 2017;8(3):88.
pubmed: 28245597
pmcid: 5368692
doi: 10.3390/genes8030088
Elmarsafawi AG, et al. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023;8(18): e169308.
pubmed: 37581943
pmcid: 10561731
doi: 10.1172/jci.insight.169308
Zhu J, et al. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity. 2012;37(4):660–73.
pubmed: 23041064
pmcid: 3717271
doi: 10.1016/j.immuni.2012.09.007
Hayes CS, et al. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol Res. 2014;2(3):274–85.
pubmed: 24778323
doi: 10.1158/2326-6066.CIR-13-0120-T
Sawant DV, et al. Adaptive plasticity of IL-10. Nat Immunol. 2019;20(6):724–35.
pubmed: 30936494
pmcid: 6531353
doi: 10.1038/s41590-019-0346-9
Okumura S, et al. Oral administration of polyamines ameliorates liver ischemia/reperfusion injury and promotes liver regeneration in rats. Liver Transpl. 2016;22(9):1231–44.
pubmed: 27102080
doi: 10.1002/lt.24471
Naito Y, et al. Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8. Sci Adv. 2023;9(20): eade0718.
pubmed: 37205755
pmcid: 10198637
doi: 10.1126/sciadv.ade0718
Whiteside TL. Clinical impact of regulatory T cells (Treg) in cancer and HIV. Cancer Microenviron. 2015;8(3):201–7.
pubmed: 25385463
doi: 10.1007/s12307-014-0159-1
Carriche GM, et al. Regulating T-cell differentiation through the polyamine spermidine. J Allergy Clin Immunol. 2021;147(1):335-348.e11.
pubmed: 32407834
doi: 10.1016/j.jaci.2020.04.037
Cheng X, et al. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023;16(1):71.
pubmed: 37415162
pmcid: 10324139
doi: 10.1186/s13045-023-01473-x
Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445–55.
pubmed: 23619691
pmcid: 3725458
doi: 10.1038/nature12034
Allavena P, et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9.
pubmed: 17913510
doi: 10.1016/j.critrevonc.2007.07.004
Squadrito ML, De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Aspects Med. 2011;32(2):123–45.
pubmed: 21565215
doi: 10.1016/j.mam.2011.04.005
Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995.
pubmed: 34209703
pmcid: 8268869
doi: 10.3390/ijms22136995
Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(3):281–6.
pubmed: 16101534
doi: 10.2174/1568010054022024
Parker KH, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723–33.
pubmed: 25164013
pmcid: 4199911
doi: 10.1158/0008-5472.CAN-13-2347
Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol. 2001;21(5):399–425.
pubmed: 11942557
doi: 10.1615/CritRevImmunol.v21.i5.10
Hu Y, et al. The regulation of nitric oxide in tumor progression and therapy. J Int Med Res. 2020;48(2):300060520905985.
pubmed: 32090657
doi: 10.1177/0300060520905985
Bloch O, et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165–75.
pubmed: 23613317
pmcid: 3742575
doi: 10.1158/1078-0432.CCR-12-3314
Matsunaga T, Saito H, Ikeguchi M. Increased B7-H1 and B7-H4 expressions on circulating monocytes and tumor-associated macrophages are involved in immune evasion in patients with gastric cancer. Yonago Acta Med. 2011;54(1):1–10.
pubmed: 24031123
pmcid: 3763800
Columba-Cabezas S, et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol. 2002;130(1–2):10–21.
pubmed: 12225884
doi: 10.1016/S0165-5728(02)00170-4
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95.
pubmed: 22378047
pmcid: 3287223
doi: 10.1172/JCI59643
Latour YL, Gobert AP, Wilson KT. The role of polyamines in the regulation of macrophage polarization and function. Amino Acids. 2020;52(2):151–60.
pubmed: 31016375
doi: 10.1007/s00726-019-02719-0
Yang Q, et al. Spermidine alleviates experimental autoimmune encephalomyelitis through inducing inhibitory macrophages. Cell Death Differ. 2016;23(11):1850–61.
pubmed: 27447115
pmcid: 5071574
doi: 10.1038/cdd.2016.71
Liu R, et al. Spermidine endows macrophages anti-inflammatory properties by inducing mitochondrial superoxide-dependent AMPK activation, Hif-1α upregulation and autophagy. Free Radic Biol Med. 2020;161:339–50.
pubmed: 33122005
doi: 10.1016/j.freeradbiomed.2020.10.029
Bussière FI, et al. Spermine causes loss of innate immune response to Helicobacter pylori by inhibition of inducible nitric-oxide synthase translation. J Biol Chem. 2005;280(4):2409–12.
pubmed: 15548540
doi: 10.1074/jbc.C400498200
Mai S, et al. Oesophageal squamous cell carcinoma-associated IL-33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase. Cell Prolif. 2021;54(2): e12960.
pubmed: 33305406
doi: 10.1111/cpr.12960
Miska J, et al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. Sci Adv. 2021;7(8): eabc8929.
pubmed: 33597238
pmcid: 7888943
doi: 10.1126/sciadv.abc8929
Dolcetti L, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40(1):22–35.
pubmed: 19941314
doi: 10.1002/eji.200939903
Nagaraj S, Youn JI, Gabrilovich DI. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol. 2013;191(1):17–23.
pubmed: 23794702
doi: 10.4049/jimmunol.1300654
Voisin MB, et al. Both expansion of regulatory GR1+ CD11b+ myeloid cells and energy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. Infect Immun. 2004;72(9):5487–92.
pubmed: 15322051
pmcid: 517443
doi: 10.1128/IAI.72.9.5487-5492.2004
Garg A, Spector SA. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis. 2014;209(3):441–51.
pubmed: 23999600
doi: 10.1093/infdis/jit469
Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21):5435–40.
pubmed: 23090118
doi: 10.1158/0008-5472.CAN-12-0569
Mondanelli G, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity. 2017;46(2):233–44.
pubmed: 28214225
pmcid: 5337620
doi: 10.1016/j.immuni.2017.01.005
Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. 2019;38(1):115.
pubmed: 30841909
pmcid: 6404286
doi: 10.1186/s13046-019-1110-6
Miyazaki Y, et al. Potential metabolite markers for pancreatic cancer identified by metabolomic analysis of induced cancer-associated fibroblasts. Cancers. 2022;14(6):1375.
pubmed: 35326527
pmcid: 8945883
doi: 10.3390/cancers14061375
Palka J, Oscilowska I, Szoka L. Collagen metabolism as a regulator of proline dehydrogenase/proline oxidase-dependent apoptosis/autophagy. Amino Acids. 2021;53(12):1917–25.
pubmed: 33818628
pmcid: 8651534
doi: 10.1007/s00726-021-02968-y
Akinjiyan FA, et al. DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Oncogene. 2023;43(3):189–201.
pubmed: 37996700
pmcid: 10786713
doi: 10.1038/s41388-023-02884-3
Ino Y, et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE. 2013;8(2): e55146.
pubmed: 23424623
pmcid: 3570471
doi: 10.1371/journal.pone.0055146
Hasebe T, et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res. 1996;87(4):385–94.
pubmed: 8641970
pmcid: 5921099
doi: 10.1111/j.1349-7006.1996.tb00234.x
Giatromanolaki A, Harris AL, Koukourakis MI. The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer. Cancer Metab. 2021;9(1):28.
pubmed: 34344457
pmcid: 8336070
doi: 10.1186/s40170-021-00264-7
Kubota S, et al. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst. 1997;89(8):567–71.
pubmed: 9106645
doi: 10.1093/jnci/89.8.567
Morrison RF, Seidel ER. Vascular endothelial cell proliferation: regulation of cellular polyamines. Cardiovasc Res. 1995;29(6):841–7.
pubmed: 7656288
doi: 10.1016/S0008-6363(96)88621-4
Li H, et al. Intracellular sources of ornithine for polyamine synthesis in endothelial cells. Amino Acids. 2016;48(10):2401–10.
pubmed: 27180260
doi: 10.1007/s00726-016-2256-6
Takigawa M, et al. Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res. 1990;50(13):4131–8.
pubmed: 1693880
Takahashi Y, Mai M, Nishioka K. alpha-Difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model. Int J Cancer. 2000;85(2):243–7.
pubmed: 10629084
doi: 10.1002/(SICI)1097-0215(20000115)85:2<243::AID-IJC15>3.0.CO;2-2
Auvinen M, et al. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res. 1997;57(14):3016–25.
pubmed: 9230217
Dai F, et al. Extracellular polyamines-induced proliferation and migration of cancer cells by ODC, SSAT, and Akt1-mediated pathway. Anticancer Drugs. 2017;28(4):457–64.
pubmed: 28157137
doi: 10.1097/CAD.0000000000000465
Ueno D, et al. Spermidine improves angiogenic capacity of senescent endothelial cells, and enhances ischemia-induced neovascularization in aged mice. Sci Rep. 2023;13(1):8338.
pubmed: 37221395
pmcid: 10205711
doi: 10.1038/s41598-023-35447-3
Martí i Líndez AA, Reith W. Arginine-dependent immune responses. Cell Mol Life Sci. 2021;78(13):5303–24.
pubmed: 34037806
pmcid: 8257534
doi: 10.1007/s00018-021-03828-4
Martí I Líndez AA, et al. Mitochondrial arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor efficacy. JCI Insight. 2019;4(24): e132975.
pubmed: 31751318
pmcid: 6975264
doi: 10.1172/jci.insight.132975
Kelly B, O’Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771–84.
pubmed: 26045163
pmcid: 4493277
doi: 10.1038/cr.2015.68
Wang YC, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70(12):4840–9.
pubmed: 20501839
doi: 10.1158/0008-5472.CAN-10-0269
Feldmeyer N, et al. Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. Int Immunol. 2012;24(5):303–13.
pubmed: 22345165
doi: 10.1093/intimm/dxs004
Kumar V, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–20.
pubmed: 26858199
pmcid: 4775398
doi: 10.1016/j.it.2016.01.004
Munder M, et al. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006;108(5):1627–34.
pubmed: 16709924
doi: 10.1182/blood-2006-11-010389
Lewis ND, et al. Arginase II restricts host defense to Helicobacter pylori by attenuating inducible nitric oxide synthase translation in macrophages. J Immunol. 2010;184(5):2572–82.
pubmed: 20097867
doi: 10.4049/jimmunol.0902436
Lewis ND, et al. Immune evasion by Helicobacter pylori is mediated by induction of macrophage arginase II. J Immunol. 2011;186(6):3632–41.
pubmed: 21296975
doi: 10.4049/jimmunol.1003431
Presnell SR, et al. Differential fuel requirements of human NK cells and human CD8 T cells: glutamine regulates glucose uptake in strongly activated CD8 T cells. Immunohorizons. 2020;4(5):231–44.
pubmed: 32385048
doi: 10.4049/immunohorizons.2000020
Son J, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–5.
pubmed: 23535601
pmcid: 3656466
doi: 10.1038/nature12040
Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890–901.
pubmed: 24523301
doi: 10.1158/1535-7163.MCT-13-0870
Mukha A, et al. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics. 2021;11(16):7844–68.
pubmed: 34335968
pmcid: 8315064
doi: 10.7150/thno.58655
Hassanein M, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res. 2013;19(3):560–70.
pubmed: 23213057
doi: 10.1158/1078-0432.CCR-12-2334
Nagarajan A, Malvi P, Wajapeyee N. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer. 2016;2(7):365–77.
pubmed: 27822561
pmcid: 5096652
doi: 10.1016/j.trecan.2016.06.002
Oh MH, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest. 2020;130(7):3865–84.
pubmed: 32324593
pmcid: 7324212
doi: 10.1172/JCI131859
Bian Y, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585(7824):277–82.
pubmed: 32879489
pmcid: 7486248
doi: 10.1038/s41586-020-2682-1
Hote PT, et al. Ethanol inhibits methionine adenosyltransferase II activity and S-adenosylmethionine biosynthesis and enhances caspase-3-dependent cell death in T lymphocytes: relevance to alcohol-induced immunosuppression. J Nutr Biochem. 2008;19(6):384–91.
pubmed: 17869084
doi: 10.1016/j.jnutbio.2007.05.010
Zhao T, Lum JJ. Methionine cycle-dependent regulation of T cells in cancer immunity. Front Oncol. 2022;12: 969563.
pubmed: 36033438
pmcid: 9399763
doi: 10.3389/fonc.2022.969563
Alexander ET, et al. A novel polyamine blockade therapy activates an anti-tumor immune response. Oncotarget. 2017;8(48):84140–52.
pubmed: 29137411
pmcid: 5663583
doi: 10.18632/oncotarget.20493
Alexander ET, et al. Polyamine blocking therapy decreases survival of tumor-infiltrating immunosuppressive myeloid cells and enhances the antitumor efficacy of PD-1 blockade. Mol Cancer Ther. 2020;19(10):2012–22.
pubmed: 32747421
pmcid: 7541445
doi: 10.1158/1535-7163.MCT-19-1116
Hayes CS, Burns MR, Gilmour SK. Polyamine blockade promotes antitumor immunity. Oncoimmunology. 2014;3(1): e27360.
pubmed: 24711956
pmcid: 3976981
doi: 10.4161/onci.27360
Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov. 2007;6(5):373–90.
pubmed: 17464296
doi: 10.1038/nrd2243
Soulet D, et al. A fluorescent probe of polyamine transport accumulates into intracellular acidic vesicles via a two-step mechanism. J Biol Chem. 2004;279(47):49355–66.
pubmed: 15208319
doi: 10.1074/jbc.M401287200
Belting M, et al. Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivital role for nitrosothiol-derived nitric oxide. J Biol Chem. 2003;278(47):47181–9.
pubmed: 12972423
doi: 10.1074/jbc.M308325200
Uemura T, et al. Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2010;299(2):G517–22.
pubmed: 20522643
pmcid: 2928537
doi: 10.1152/ajpgi.00169.2010
van Veen S, et al. ATP13A2 deficiency disrupts lysosomal polyamine export. Nature. 2020;578(7795):419–24.
pubmed: 31996848
doi: 10.1038/s41586-020-1968-7
Sekhar V, Andl T, Phanstiel O. ATP13A3 facilitates polyamine transport in human pancreatic cancer cells. Sci Rep. 2022;12(1):4045.
pubmed: 35260637
pmcid: 8904813
doi: 10.1038/s41598-022-07712-4
Hamouda NN, et al. ATP13A3 is a major component of the enigmatic mammalian polyamine transport system. J Biol Chem. 2021;296: 100182.
pubmed: 33310703
doi: 10.1074/jbc.RA120.013908
Vrijsen S, et al. ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proc Natl Acad Sci USA. 2020;117(49):31198–207.
pubmed: 33229544
pmcid: 7733819
doi: 10.1073/pnas.1922342117
Moriyama Y, et al. Vesicular polyamine transporter as a novel player in amine-mediated chemical transmission. Biochim Biophys Acta Biomembr. 2020;1862(12): 183208.
pubmed: 32004521
doi: 10.1016/j.bbamem.2020.183208
Madan M, et al. ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers. Am J Cancer Res. 2016;6(6):1231–52.
pubmed: 27429841
pmcid: 4937730
Hiasa M, et al. Identification of a mammalian vesicular polyamine transporter. Sci Rep. 2014;4:6836.
pubmed: 25355561
pmcid: 4213795
doi: 10.1038/srep06836
Takeuchi T, et al. Vesicular polyamine transporter mediates vesicular storage and release of polyamine from mast cells. J Biol Chem. 2017;292(9):3909–18.
pubmed: 28082679
pmcid: 5339771
doi: 10.1074/jbc.M116.756197
Ask A, Persson L, Heby O. Increased survival of L1210 leukemic mice by prevention of the utilization of extracellular polyamines. Studies using a polyamine-uptake mutant, antibiotics and a polyamine-deficient diet. Cancer Lett. 1992;66(1):29–34.
pubmed: 1451093
doi: 10.1016/0304-3835(92)90276-2
Corral M, Wallace HM. Upregulation of polyamine transport in human colorectal cancer cells. Biomolecules. 2020;10(4):499.
pubmed: 32218236
pmcid: 7226413
doi: 10.3390/biom10040499
Gitto SB, et al. Difluoromethylornithine combined with a polyamine transport inhibitor is effective against gemcitabine resistant pancreatic cancer. Mol Pharm. 2018;15(2):369–76.
pubmed: 29299930
doi: 10.1021/acs.molpharmaceut.7b00718
Muth A, et al. Polyamine transport inhibitors: design, synthesis, and combination therapies with difluoromethylornithine. J Med Chem. 2014;57(2):348–63.
pubmed: 24405276
doi: 10.1021/jm401174a
Alexander ET, et al. Loss of anti-tumor efficacy by polyamine blocking therapy in GCN2 null mice. Biomedicines. 2023;11(10):2703.
pubmed: 37893077
pmcid: 10604246
doi: 10.3390/biomedicines11102703
Bergeron RJ, et al. Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives. J Med Chem. 2000;43(2):224–35.
pubmed: 10649978
doi: 10.1021/jm990375z
Tebbutt NC, et al. A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2018;36: e16231.
doi: 10.1200/JCO.2018.36.15_suppl.e16231
Murray-Stewart TR, Woster PM, Casero RA. Targeting polyamine metabolism for cancer therapy and prevention. Biochem J. 2016;473(19):2937–53.
pubmed: 27679855
doi: 10.1042/BCJ20160383
Holbert CE, et al. Expanded potential of the polyamine analogue SBP-101 (diethyl dihydroxyhomospermine) as a modulator of polyamine metabolism and cancer therapeutic. Int J Mol Sci. 2022;23(12):6768.
doi: 10.3390/ijms23126798
Singhal N, et al. SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2021;39(15 suppl). https://doi.org/10.1200/JCO.2021.39.15_suppl.412 .
Harbison RA, et al. Interrogation of T cell-enriched tumors reveals prognostic and immunotherapeutic implications of polyamine metabolism. Cancer Res Commun. 2022;2(7):639–52.
pubmed: 36052016
pmcid: 9432485
doi: 10.1158/2767-9764.CRC-22-0061
Guo T, et al. PGC-1α inhibits polyamine metabolism in Cyclin E1-driven ovarian cancer. Cancer Med. 2019;8(18):7754–61.
pubmed: 31657115
pmcid: 6912055
doi: 10.1002/cam4.2637
Chen M, et al. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma. Front Immunol. 2022;13:1048204.
pubmed: 36505496
pmcid: 9732944
doi: 10.3389/fimmu.2022.1048204
Tormey DC, et al. Biological markers in breast carcinoma. I. Incidence of abnormalities of CEA, HCG, three polyamines, and three minor nucleosides. Cancer. 1975;35(4):1095–100.
pubmed: 1116102
doi: 10.1002/1097-0142(197504)35:4<1095::AID-CNCR2820350412>3.0.CO;2-7
Fahrmann JF, et al. A MYC-driven plasma polyamine signature for early detection of ovarian cancer. Cancers. 2021;13(4):913.
pubmed: 33671595
pmcid: 7927060
doi: 10.3390/cancers13040913
Tsoi TH, et al. Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. PLoS ONE. 2016;11(9): e0162217.
pubmed: 27598335
pmcid: 5012650
doi: 10.1371/journal.pone.0162217
Umemori Y, et al. Evaluating the utility of N1, N12-diacetylspermine and N1, N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers. Clin Chim Acta. 2010;411(23–24):1894–9.
pubmed: 20655890
doi: 10.1016/j.cca.2010.07.018
Yoshida K, et al. Metabolome analysis reveals a diversity of cancer tissues in advanced epithelial ovarian cancer. Cancer Cell Int. 2021;21(1):314.
pubmed: 34134729
pmcid: 8207638
doi: 10.1186/s12935-021-02014-7
Saulnier Sholler GL, et al. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PLoS ONE. 2015;10(5): e0127246.
pubmed: 26018967
pmcid: 4446210
doi: 10.1371/journal.pone.0127246
Lewis EC, et al. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020;147(11):3152–9.
pubmed: 32391579
pmcid: 7586843
doi: 10.1002/ijc.33044